First, contact us using our email address or the website contact form. Describe us your project and we will discuss different proposals according to your needs. Once we agreed on the conditions, we will send you an official quotation describing the services, which has to be signed and sent back to us.

Once we received the signed quotation, the project starts. We will ask you to fill the Product Form with information about the samples to be tested and you can proceed with the shipment. Once we receive the samples in our facilities, we will proceed with the experimentation. In the meantime between signing the quotation and receiving the sample, we will prepare reagents (in vitro) or the panel recruitment (clinical) to start working as soon as possible after receiving your samples.

In vitro efficacy testing: Depending on the specific protocol to be performed, small samples (200-400 µg in powder or µL in liquid) may be usually required. For longer protocols, larger samples (0.5-1 gram or 4-6 mL) may be required.

Clinical efficacy testing: The number of samples required for the clinical tests depend on the number of volunteers included in the study. We usually ask for “Number of Volunteers + 5 extra (to solve possible problems)” samples. The necessary quantity of sample depends on the specific application of the product, being the standard application for face around 0.5 grams (3-4 mg/cm2). Therefore, we usually recommend 30 mL for 1-month with twice daily application in face and 60 mL for 2-months treatment.

In vitro safety testing: According to the specific protocol, 2 different samples of 0.5-1 gram (powder) or 5-10 mL (liquid), will be required.

Unless agreed different conditions, all of our clinical studies include in the quoted price the self-assessment questionnaire (maximum 25 questions to be designed with the client), HD macroscopic pictures from a professional photography setup, marketing images according to the specific biomarkers (wrinkles, dark spots, neck jowls, etc.), and dermatological or ophthalmological surveillance, for all of the volunteers at all the timepoints.

Upon request to the client, a marketing presentation with the images/videos of the different volunteers in power point or access format, may be also prepared and delivered, together with the final results.

Prices do not include VAT neither other taxes, and are based on the current rates at the time of sending the offer to the client. Applicable taxes are the ones in force at the billing date.

Dermaclaim’s payment conditions are fifty percent (50 %) of the total amount budgeted when signing the quotation, and the remaining fifty percent (50 %) upon delivery of the final results report, except previously agreed conditions; using bank transfer in favor of Dermaclaim Lab S.L., with a maximum period of 30 days invoice date.

Dermaclaim is certified in Quality Management System (ISO 9001:2015) since August 2022, Crédit d’Impot Recherche (French Research Tax Credit) since December 2023, and Information Security Management System (ISO 27001:2022) since August 2024. Throughout 2025, Spanish Innovative SME Enterprises seal will be also obtained.

It is also important to remark that clinical protocols are in accordance with the Scientific Committee on Consumer Safety (SCCS) guidance, meeting all international standards for research studies involving human subjects, Structure and Content of Clinical Study Reports from ICH Harmonised Tripartite Guideline; International Recommendations ICH Topic E6, European Parliament and Council Guideline 2001/20/CE, the Good Clinical Practices (ICH-GCP), and the World Medical Association. They are conducted pursuant to the Declaration of Helsinki (1964), with the amendments of Tokyo (1975), Venice (1983), Hong Kong (1989), South Africa (1996), Edinburgh (2000), Seoul (2008), and Fortaleza (2013).

Additionally, when required by the client, the clinical protocol could be submitted for approval to the Ethical Committee, being this necessary for potential journal publications. Ethical Committee approval is mandatory for oral intake treatments, but not for topical application projects.

Moreover, in vitro bioassays and clinical studies follow the “Guidelines for the Evaluation of the Efficacy of cosmetic Products”, COLIPA (May, 2008).

Since its start on October 2021, Dermaclaim has performed more than 600 projects for more than 100 clients worldwide (USA, Australia, India, Brazil, South Africa, Colombia, Germany, United Kingdom, Italy, Switzerland, Israel, France, Spain, Norway, Lebanon, New Zealand…), both for active ingredients suppliers and end-product manufacturers.

In vitro and clinical results are recognized all around the world for all the different regulations, including Europe (Regulation EC N° 1223/2009), United States (Food, Drug, and Cosmetic Act and the Fair Packaging and Labeling Act), China (Cosmetics Supervision and Administration Regulations, CSAR), Australia (Australian Competition and Consumer Commission, ACCC), etc.

Preliminary results are immediately sent to the customer, after finishing the study and processing all the data. The final report is usually sent 4-6 days after the preliminary results. Find below more information about the specific timings for each type of testing:

In vitro efficacy testing: The final report is usually delivered in 4-5 weeks after sample reception. However, there are simple protocols that could be conducted in 1-2 days and the report delivered in the same week of receiving the sample. More complex protocols may take longer, according to each specific project.

Clinical testing: The normal timings for an accurate panel recruitment are 4 weeks, including 2-weeks previous washout phase. After tha, 4-8 weeks for the treatment and 6-8 days to process all the data and deliver the complete final report.

In vitro safety testing: The final report is usually delivered in 3-4 weeks after sample reception for most of the protocols, excluding Ames Test OECD 471 and Franz Cell Absorption 428 (5-6 weeks).

The ownership of the results obtained after contracting our services and the industrial and intellectual property rights that may be arised from them, belong exclusively to the customer, unless Dermaclaim and the Client agree other different conditions.

Dermaclaim can participate in a scientific publication derived from the studies performed, but this decision will depend only on the customer. Dermaclaim has no rights on the obtained results.

Dermaclaim Lab S.L. represents fully independent testing facilities committed to the highest standards of unbiased testing and reporting. Dermaclaim Lab S.L. is not in partnership, affiliation and/or association, in any way, with any other corporation, company, sole proprietorship, partnership, client, laboratory, and/or any other business entity. Dermaclaim Lab S.L. is not legally responsible or bound to any claim(s) provided by a third party claiming any kind of association with Dermaclaim Lab S.L.

All original raw data, including data sheets, clinical protocols, technical procedures, laboratory notebooks, correspondence files, copies of final reports, and remaining samples, are maintained on the premises of Dermaclaim Lab S.L., in limited access marked storage files. Altogether, including the information provided by the sponsor, volunteers’ data, information about materials, reagents or methodology, and all the information generated by Dermaclaim Lab S.L. (statistical analysis, graphical representations, etc.) is considered Confidential, and will not be shared with third parties.

To prevent loss of and protect intellectual property, the final report is electronically signed using the official signature of Dermaclaim Lab S.L. (VAT: B16909699). Any attempt to remove the signature will irreversibly damage the label and leave an immediate trace, thus invalidating the document. Only reports containing the Dermaclaim Lab S.L. electronic signature intact, will be recognized by Dermaclaim Lab S.L. as a certified original.

According to customer’s needs, it is very common to start conversations by signing a Non-disclosure Agreement (NDA), in order to protect the confidentiality of all the information and results.

Dermaclaim will store the extra samples that were not necessary for the development of the contracted services during a period of twelve (12) months, unless otherwise established with the customer or due to regulatory international guidelines.

Once this period is over, the samples will be unusuable and disposed, according to the corresponding regulations. Dermaclaim is not responsible for the possible variations of the samples during the period of storage.